Articles tagged with Lung Cancer
Researchers have identified compounds that can reduce cancer incidence, including thiazolidinediones for type-2 diabetes patients. Synthetic triterpenoids like CDDO-Im also show potent protection against liver tumors.
Researchers have developed a method using cheek cells to detect lung cancer with high sensitivity and specificity. The test uses Automated Quantitative Cytometry (AQC) to analyze buccal cell nuclei and predict the likelihood of cancer presence.
The Lance Armstrong Foundation has established an endowed chair in oncology at Indiana University, providing $1.5 million for research and program development. Dr. Einhorn, a renowned expert on urologic cancer, will lead the initiative to improve patient therapies and quality of life.
New therapy Iressa shows no significant survival improvement for NSCLC patients, but offers better outcomes for Asian and non-smoking patients. The study results provide insight into the effectiveness of EGFR inhibitors in specific patient groups.
A recent study published in The Lancet found that consuming cruciferous vegetables may protect against lung cancer, particularly for individuals with inactive forms of specific genes. The research revealed a 33% protective effect in those with an inactive GSTM1 gene and a 37% effect in those with an inactive GSTT1 gene.
Researchers at Ohio State University discovered that restoring the missing or silenced WWOX gene can slow or stop lung-cancer cell growth. The study showed that reactivating the gene is highly effective in stopping human lung tumor growth in mice, suggesting a potential therapeutic approach for lung cancer treatment.
Researchers found that gene therapy using manganese superoxide dismutase plasmid liposome (MnSOD-PL) protected healthy tissue from damage during and after radiation retreatment. The therapy significantly improved survival rates and reduced side effects in lung cancer patients.
A recent study found that African-American women with faulty cell cycle checkpoints are at a nearly five-fold increased risk of developing lung cancer. The study suggests that less effective cell cycle checkpoints may lead to genetic instability and increased cancer risk in this population.
The annual report shows cancer death rates decreasing for 12 of the top 15 cancers in men and nine in women, with lung cancer remaining a leading cause. Overall incidence rates have been stable since 1992, but breast cancer incidence has increased due to rising rates for six other cancers.
A population-based study with up to 31 years of follow-up found that reducing tobacco consumption from heavy smoking can lower lung cancer risk. Heavy smokers who cut their daily intake by half saw a 27% reduction in lung cancer risk compared to unchanged heavy smokers.
A study found that increased intake of phytoestrogens, found in soy products and certain fruits and vegetables, was associated with a lower risk of lung cancer. The study analyzed data from over 1,600 patients with lung cancer and matched healthy controls, revealing sex-specific differences in protective effects.
A large US population study found that eating foods with phytoestrogens, such as soy and fruits, may lower lung cancer risk. The study, involving over 3,500 participants, discovered a 46% reduced risk of developing lung cancer among those who consumed the highest amount of phytoestrogen-rich foods.
A study tracking 43,000 men and women found that light smoking (1-4 cigarettes/day) significantly increases the risk of coronary artery disease and lung cancer. Women are almost five times as likely to die from lung cancer compared to non-smokers.
A study of nearly 60,000 French women found that beta-carotene intake was inversely associated with tobacco-related cancer risk in never-smokers, but increased the risk in former and current smokers. The researchers also calculated that the absolute rates of tobacco-related cancers over 10 years varied significantly between nonsmoking ...
A Phase II study found erlotinib to be relatively well-tolerated and demonstrated encouraging activity in previously untreated patients 70 years or older with advanced lung cancer. The study showed a median survival of 46 weeks, with 60% of patients experiencing partial response or stable disease.
Researchers discovered that compounds from cruciferous veggies can slow down benign to malignant tumors in mice, suggesting potential protection against lung cancer development. The studies also found that these compounds can push human lung cells to commit 'suicide', stopping fast-growing cancer cells.
Researchers at UT Southwestern Medical Center found a compound called GRN163L that blocks the enzyme telomerase, which keeps cells immortal and implicated in most human cancers. The compound works rapidly and in doses considered reasonable for therapy.
Researchers at Thomas Jefferson University found that giving chemotherapy and radiation together from the start may help patients with locally advanced lung cancer live longer. The study compared three treatment approaches and showed that combining chemotherapy and radiation improved patient outcomes.
Research finds that neutropenia, a type of hematological toxicity, is associated with increased overall survival in patients with advanced non-small cell lung cancer. Prospective trials are needed to assess whether drug dosing guided by toxic effects could improve chemotherapy efficacy.
Researchers explore specific tobacco cancer biochemistry and epidemiology, shedding light on why some smokers develop lung cancer while others do not. Key findings include the role of polycyclic aromatic hydrocarbons in forming lesions that lead to gene mutations.
A study published in JAMA Network found that a diagnostic strategy combining Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) and mediastinoscopy can identify more patients with tumor invasion or lymph node metastases, reducing unnecessary thoracotomies by 16%.
Researchers found that gefitinib (Iressa) was significantly effective in treating lung cancer cells containing a mutant EGFR molecule, while cetuximab (Erbitux) had little effect. The study suggests that mutations in the targets of designer drugs critically influence their effectiveness.
Researchers found that gefitinib was more effective at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR. In contrast, cetuximab showed no significant response in patients with EGFR mutations.
Scientists at Ohio State University created a mouse model of lung cancer that loses the FHIT gene's protein early in development, leading to larger and more numerous tumors. The study suggests that even low levels of the protein might prevent lung cancer.
Researchers design dual-chamber nanocell to deliver anti-angiogenic and chemotherapy drugs to tumors, reducing toxicity and improving survival rates. The new approach shows great potential in treating two types of cancers, with mice surviving up to 65 days without severe side effects.
Researchers found that PGE2 up-regulates T-regulatory cells, suppressing immune function and fueling cancer growth. The study suggests using COX-2 inhibitors like Celebrex to augment immune responses in cancer patients.
A trial involving 731 patients found that treatment with erlotinib resulted in longer survival compared to a placebo, with patients on erlotinib surviving an average of 6.7 months versus 4.7 months. Erlotinib was also well-tolerated and improved physical function, quality of life, and symptoms.
A new report by the European Society for Medical Oncology reveals that female lung cancer death rates in Europe are still rising, despite a 16% increase between 1990-2001. However, trends in some countries and among younger women show a decline, suggesting future hope for reducing this epidemic.
Researchers at Dana-Farber Cancer Institute have identified regions of irregular gene copy numbers in non-small cell lung cancer cells, pointing to a large number of previously unknown cancer-causing genes. The study also found that certain genes, including p63, play a role in the development of squamous cell carcinomas.
A new study finds that post-surgical chemotherapy significantly improves five-year survival rates for patients with non-small cell lung cancer, reducing cancer recurrence by 49% compared to surgery alone. The treatment is inexpensive and has limited side effects, paving the way for a new standard of care.
Christine Chung, a Vanderbilt researcher, has won the Damon Runyon Research Foundation/Lilly Clinical Investigator Award to support her work on genetic profiling for head and neck cancers. The award will provide funding for DNA microarray technology to predict tumor recurrence and response to chemotherapies.
A study found that relatives of black patients with early-onset lung cancer had a risk of developing lung cancer that was more than twice as high as those of white patients. Smokers with a family history of early-onset lung cancer also faced an increased risk, especially after age 60.
Researchers at NIST have developed a new DNA sequencing chip that detects mtDNA changes associated with early cancer. The chip promises faster, easier interpretation, and higher throughput than current methods, potentially revolutionizing early clinical cancer diagnosis.
Researchers at UNC Chapel Hill found that radiation exposure at older ages significantly increases the risk of lung cancer among Hanford nuclear workers. The study analyzed data from 26,389 workers hired between 1944 and 1978 and identified 2,265 cancer deaths.
A new study finds that tobacco smoke exposure is responsible for most premature cancer deaths among African-American males, with Southern and Midwestern states showing greater burdens due to weaker tobacco control policies. The study suggests that strengthening tobacco control measures can help reduce these deaths.
A study of young adults found a strong association between asthma and panic disorder, with active asthma predicting subsequent panic disorder. The 'electronic nose' technology also showed promise in detecting lung cancer by analyzing exhaled breath samples.
A study by the University of California - Davis Health has demonstrated a significantly improved survival rate for locally advanced lung cancer patients using a chemotherapy regimen that includes docetaxel. The study showed a five-year survival rate of 29 percent, surpassing previous results.
A landmark Phase III trial found that concurrent chemotherapy and radiation therapy followed by surgery significantly improves lung cancer patient survival. Five-year survival rates were 36% for patients with partial lung removal and 27% for those who underwent concurrent treatment.
A national population-based study of 16,036 lung cancer patients found that Hispanics with curable stage I lung cancer had poorer lung cancer specific survival rates and worse all-cause mortality than white persons. This disparity was largely explained by lower surgical resection rates among Hispanics and a higher probability of being ...
A recent Mount Sinai study found that Hispanic patients with stage I non-small cell lung cancer have a significantly lower five-year survival rate of 54% compared to white patients at 62%. This disparity is largely attributed to unequal access to surgical resection, as well as higher rates of advanced-stage diagnosis.
The Lancet suggests that aggressive tobacco taxation policies are needed to reduce the demand for tobacco products, which cause 5 million deaths annually. Annual price increases of 50% can lead to a reduction in tobacco consumption by 4-8% in high-income and low-middle income countries, respectively.
Researchers found that advanced NSCLC patients with high EGFR gene copy number, protein expression, or mutations respond better to gefitinib. High EGFR gene copy number is associated with prolonged survival and disease control.
A new study found that increasing Pap screening adherence and improving its accuracy could reduce the incidence of invasive cervical cancer among women with access to screening. The study also identified factors associated with screening failure, including lack of Pap testing and unrelated outpatient visits.
Researchers have developed a new technology that uses DNA methylation profiling to detect cells in the lung likely to become cancerous. The method combines high-powered microscopes with the capability of analyzing many samples at a time, providing a breakthrough in identifying high-risk individuals.
Research investigates associations between male breast cancer, human papillomavirus (HPV) infections, and genetic variants in DNA repair genes. Ionizing radiation exposure is linked to higher male breast cancer incidence among atomic bomb survivors, while HPV detection is strongly associated with HIV status. Genetic polymorphisms in DN...
University scientists have discovered ways to detect areas of instability in DNA that can lead to cancer. By applying this technology to pre-cancerous lesions, they've found that DNA damage occurs very early in the carcinogenic process, highlighting those at risk of developing cancer.
The American Cancer Society no longer recommends testing for early lung cancer detection, citing reduced risks after quitting smoking. However, a new position statement strongly advocates for asymptomatic screening in clinical trials or informed discussion of options.
Researchers found that smokers receiving multiple abnormal CT scans were more likely to quit smoking and remain smoke-free. The study suggests that abnormal lung cancer screening results can serve as a psychological push for smokers to quit, leading to increased success rates.
Researchers are developing a vaccine using dendritic cells to boost the immune system against lung cancer recurrence. The study enrolls patients for two years, with promising previous results, aiming to treat 30 new patients.
A recent study suggests that CT lung cancer screening may not be as beneficial as previously thought, as many early-stage cancers detected through CT are slow-growing and unlikely to have been fatal. The study found that unnecessary surgical procedures and expenses were also significant drawbacks.
Researchers at Yale University have discovered that the microRNA let-7 regulates the Ras cancer gene by binding to its mRNA and inhibiting translation. This finding has significant implications for understanding cancer progression and developing new treatments, including gene therapy with let-7.
A recent multi-center study found a direct link between residential radon exposure and increased lung cancer risk, with risks estimated to be 11-21% higher than average levels. The study, pooling data from seven North American studies, supports earlier findings and provides unambiguous evidence of the association.
Mutations in the EGFR gene are more common in people with lung cancer who never smoked, and these mutations may predict a dramatic response to certain drugs. The study's findings suggest two distinct molecular pathways involved in lung cancer formation, one affecting smokers and the other non-smokers.
A recent study found that epidermal growth factor receptor (EGFR) gene mutations are more common in never smokers, females, and patients of East Asian ancestry. The mutations were also associated with increased sensitivity to gefitinib and erlotinib, tyrosine kinase inhibitors.
Researchers at UT Southwestern will investigate the consequences of space radiation exposure on human health, with a focus on lung cancer and its prevention. The $9.8 million grant will enable the development of new cell systems and animal models to study high-energy particles in space.
A recent study reveals that cancer cells can develop resistance to gefitinib by mutating the EGFR gene, altering the drug's binding pocket and rendering it ineffective. This finding could lead to the development of new targeted therapies to treat non-small cell lung cancer.
Researchers found that tumors developing secondary resistance to Tarceva and Iressa had an additional EGFR mutation, rendering the drugs ineffective. The discovery highlights the need for alternative targeted therapies for patients with KRAS mutations.
Scientists found that tumors from six patients with non-small cell lung cancer who initially responded to gefitinib or erlotinib but relapsed carried activating mutations in the EGFR gene. The resistant tumor cells also carried a second mutation in the EGFR gene, which causes resistance to these drugs.
The report reveals that nearly 2.9 million new cases of cancer were diagnosed in Europe in 2004, with lung cancer being the most common form. Breast cancer is also on the rise, while stomach cancer rates are falling. The study emphasizes the need for a joint European effort to combat these diseases.
New studies suggest that blocking estrogen may be essential to slowing the spread of lung cancer. Researchers found that a combination therapy targeting both estrogen and epidermal growth factor receptors resulted in a 59% tumor volume decrease.